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Abstract
Purpose Immunological and molecular evaluation of a pa-
tient presenting with recurrent infections caused by Strepto-
coccus pneumoniae and low complement component 3 (C3)
levels.
Methods Immunological evaluation included complement
components and immunoglobulin level quantification as
well as number and function of T cells, B cells and neutro-
phils. Serotype-specific immunoglobulin G antibodies
against S. pneumoniae capsular polysaccharides were quan-
tified by ELISA in serum samples before and after vaccina-
tion with unconjugated polysaccharide vaccine. For the
molecular analysis, genomic DNA from the patient and
parents were isolated and all exons as well as exon-intron
boundaries of the C3 gene were sequenced by Sanger
sequencing.
Results A 16-year-old male, born to consanguineous
parents, presented with recurrent episodes of pneumonia
caused by S. pneumoniae and bronchiectasis. The patient
showed severely reduced C3 and immunoglobulin A levels,
while the parents showed moderately reduced levels of C3.
Mutational analysis revealed a novel, homozygous missense
mutation in the C3 gene (c. C4554G, p. Cys1518Trp),
substituting a highly conserved amino acid in the C345C
domain of C3 and interrupting one of its disulfide bonds.
Both parents were found to be carriers of the affected allele.
Vaccination against S. pneumoniae resulted in considerable
clinical improvement.
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Conclusions We report a novel homozygous mutation in the
C3 gene in a patient with concomitant selective IgA
deficiency who presented with a marked clinical im-
provement after vaccination against S. pneumoniae. This
observation underlines the notion that vaccination
against this microorganism is an important strategy for
treatment of PID patients, particularly those presenting
with increased susceptibility to infections caused by this
agent.
Keywords Complement deficiency . complement component
3 . Streptococcus pneumoniae . primary immunodeficiency
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Primary immunodeficiencies (PIDs) are a heterogeneous
group of inherited disorders of the immune system leading
to enhanced susceptibility to infections [1]. The complement
system is a crucial component of innate immunity and one
of the main effector mechanisms of antibody-mediated im-
munity (reviewed in [2]).
Inherited complement deficiencies represent immunode-
ficiencies characterized by susceptibility to invasive infec-
tions by encapsulated bacteria such as Streptococcus
pneumoniae (reviewed in [3–5]). The third component of
the complement system (C3) is indispensable to all the
known pathways of complement activation. C3 deficiency
(OMIM: 120700) is a rare PID, leading to predisposition to
recurrent pyogenic infections [1, 4].
A few biallelic defects in the C3 gene have been de-
scribed in patients suffering not only from S. pneumoniae
infections [6–12] but also from autoimmune and immune-
complex-related disorders, in particular affecting the kidney
[13–15]. A similar phenotype can also be observed in
patients with deficiency of complement factor H or I,
respectively [5].
Here, we describe a patient with selective immunoglob-
ulin A (IgA) deficiency presenting with recurrent airway
infections caused by S. pneumoniae and bronchiectasis with
no autoimmune or immune complex manifestations. Our
molecular analyses revealed that the patient suffers from




This study has been approved by the Ethics Committee at
the Medical University of Vienna, Austria. The patient and
the other family members gave informed consent to the
genetic analysis described here. Clinical data from the
patients were provided in anonymized form by the respon-
sible physician(s).
Determination of Antibody Titers Against Streptococcus
pneumoniae
Measurement of capsular polysaccharide serotype-specific im-
munoglobulin G (IgG) antibodies against S. pneumoniae was
performed by enzyme-linked immunosorbent assay (ELISA)
in serum samples before and 6 weeks after vaccination with
PNEUMO 23® (unconjugated polysaccharide vaccine against
S. pneumoniae) as described previously with minor modifica-
tions [16]. All sera were analyzed in duplicates in the same
ELISA run. In order to eliminate antibodies to cell wall poly-
saccharides, microtiter plates were coated with capsular poly-
saccharide antigens (from the American Type Culture
Collection (ATCC), Rockville, MD) and the samples were
pre-incubated overnight with species-specific common cell
wall polysaccharide from S. pneumoniae (CWPS; C-
polysaccharide purified; Statens Serum Institute, Denmark).
Antibody concentrations are indicated as the percentage of
reference serum, the hyperimmune plasma pool (U.S. Pneu-
mococcal Reference serum FDA7 CBER, Bethesda, MD) in
units per milliliter (U/mL), where the reference plasma pool
represents 100 U/mL for each serotype. Since patients with
high pre-immunization titers may not generate a drastic in-
crease after immunization, the final concentration of antibodies
after immunization (regardless of increase from pre-
immunization concentration) was taken into account. A mini-
mal concentration of 20 U/mL in at least 50 % of the serotypes
tested was considered as a positive response to the vaccination.
This criterion was selected according to results obtained in 40
healthy Turkish children (age range: 5 to 15 years; median:
10 years and mean, 9.7 years) (O. Sanal, unpublished data).
Molecular Analysis
Genomic DNA was isolated from whole blood obtained
from the patient and parents using a commercially available
kit (Wizard® Genomic DNA Purification Kit, Promega Cor-
poration) according to the manufacturer’s instructions.
The primers used for sequencing of the C3 gene were
previously described by Goldberg et al. [10] with one addi-
tional pair covering part of exon 41 and the 3’UTR. This
additional pair has the following sequences: forward 5′-
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ctcagctacatcatcgggaag-3′ and reverse 5′-ccttggctaaagaagtcagca-
3′. All primers were purchased from Sigma Aldrich, Austria.
Capillary sequencing was performed with the Big Dye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems, Germany) and analyzed on a 3130×l Genetic Ana-
lyzer (Applied Biosystems). For sequence analysis,
Sequencher DNA Software 4.10.1 (Gene Codes Corpora-
tion, USA) was used. The nucleotide variations found were
further sequenced on both parents in order to evaluate the
segregation. PolyPhen2 (Polymorphism Phenotyping v2,
http://genetics.bwh.harvard.edu/pph2/) and SIFT (J. Craig
Venter Institute, http://sift.jcvi.org/) were used to predict
the effect of the mutation on protein function.
Phylogenetic conservation was assessed using protein
sequences from Ensembl (http://www.ensembl.org) and
UniProt (http://www.uniprot.org/) and aligned using Uni-
Prot multiple sequence alignment tool. For the protein mod-
eling, we used Molsoft ICM Browser Pro software and a
crystal structure model of the C3 convertase (2WIN) from
the Protein Database website (http://www.rcsb.org/pdb/).
Results
Clinical Characterization of Patient and Family
At the age of 16 years, a male Turkish patient born to
consanguineous parents (first-degree cousins) as the third
of eight children, was admitted to hospital with a history of
fever, cough and respiratory distress for 48 h. Physical
examination revealed weight and height within normal
range, a wound scar resulting from a thoracotomy per-
formed at the age of 6 months, and crackles and bronchial
respiratory sounds. A chest X-ray revealed pneumonia
(Fig. 1) but no specific infectious agent could be isolated.
With regards to the past medical history, the patient had
needed a tube thoracostomy due to pleural effusion at the age
of 6 months and had suffered from recurrent lower respiratory
infections with a frequency of 4 to 5 times per year. At the age
of 8 years, bronchiectasis was detected and posterolateral
segmentectomy in the left lower lobe was performed. Subse-
quently, the frequency of infections was reduced however, in a
period of 6 years (from 14 to 20 years) he still presented with
two episodes of otitis media and 8 episodes of lower respira-
tory tract infections for which hospitalization was necessary.
At the age of 20 years, the patient was vaccinated for S.
pneumoniae and has not suffered from severe infections or
needed hospitalization since (7 years of follow up so far).
The patient has never presented with hematuria, hyper-
tension or other clinical feature indicative of renal involve-
ment or autoimmune disorder.
Notably, two of his brothers had died during the neonatal
period for unknown reasons. His parents, three brothers and
two sisters are healthy (see Fig. 2a and Supplementary
Figure 1 for pedigrees).
Laboratory Evaluation
The patient had normal red cell counts but elevated eryth-
rocyte sedimentation rate (52 mm/h; reference values: 0–
15 mm/h) and C-reactive protein levels (66 mg/dL; refer-
ence values: 8.5–10.6 mg/dL), respectively. Total leuko-
cyte (7500/mm3) and lymphocyte counts (3500/mm3)
were within the normal range. Routine urine analysis
and renal function were unremarkable (see Table 1 for
blood urea nitrogen and creatinine levels; urine analysis
data are not shown). Immunoglobulin M, G and E levels
were within the normal range as well as the IgG sub-
classes, while serum IgA levels were reduced (Table 1).
As there were no signs or symptoms of autoimmunity,
autoantibody levels were not evaluated.
Six weeks after vaccination for S. pneumoniae (20 years
of age), the patient demonstrated a positive antibody
response (Table 2).
C3 levels were severely decreased in the patient, varying
from 8 to 19 mg/dL at 6 different measurements (Table 1;
reference values: 90–180 mg/dL), with absent complement
hemolytic activity measured using the CH50 test. The other
complement levels (C1, C2, C4, C5, C6, C7, C8, C9, Factor
H and Factor I) were found to be normal (see Table 1 for C4;
other data not shown). The proliferative response of periph-
eral blood lymphocytes to phytohemagglutinin and the
spontaneous and stimulated nitroblue tetrazolium test were
normal (Table 1). The parents showed normal levels of IgA
and normal CH50, but reduced C3 levels (63 mg/dL and
Fig. 1 Lung radiography of the patient at admission showing
pneumonia in the left lung and bronchial wall thickening on the
right lung
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71 mg/dL), respectively. Details of the laboratory findings
of the patient and his parents are shown in Table 1.
Mutation Identification in the C3 Gene
The patient was evaluated for an underlying mutation in the
C3 gene. Sanger sequencing identified a homozygous mis-
sense mutation in exon 38 (c. C4554G, p. Cys1518Trp).
Molecular segregation analysis showed perfect segregation,
with both parents and three siblings being carriers of one
affected allele (Fig. 2a and Supplementary figure 1). To date,
this variant has neither been annotated as a polymorphism in
NCBI (http://www.ncbi.nlm.nih.gov/), nor in UCSCGenomic
Bioinformatics site (http://genome.ucsc.edu/) or Ensembl
(http://www.ensembl.org), respectively. Polyphen2 and Sort-
ing Intolerant from Tolerant (SIFT) analysis predict that the
substitution of cysteine to tryptophan at position 1518 of C3 is
very likely to affect protein function, with the maximum score
in both analyses (1.000 in Polyphen2 and 0.000 in SIFT,
respectively). As indicated in Fig. 2b, the cysteine residue at
position 1518 is conserved among vertebrates [17] and it has
been shown to form a disulfide bridge with cysteine 1590 [17,
18]. In Fig. 3, a detail of the C345C domain in complex with
Factor B (model based on the PDB 2WIN) is depicted and the
localization of the disulphide bridge is shown.
Discussion
The complement system is a protein network crucial for both
innate and adaptive immune responses. C3 is the conver-
gence point for all the known complement activation cas-
cades, resulting in cleavage of C3 into C3a (anaphylatoxin)
and C3b (reviewed in [2]). The latter is an important product
for opsonization of bacteria including encapsulated bacteria
such as S. pneumoniae [18, 19], for amplification of com-
plement activation through the alternative pathway, where
the association of C3b with complement factor B is essential,
and for cell lysis through the formation of C5 convertase
(reviewed in [2]). Patients with C3 deficiency frequently
develop severe episodes of recurrent pneumonia, meningitis
or sepsis. Clinically, these patients present at an early age
with overwhelming infections caused by S. pneumoniae [4, 5].
Autoimmunity and other immune manifestations, frequently
affecting the kidney, are also observed in C3-deficient patients
[13–15].
Since the parents of the patient described here were first-
degree cousins and the index patient’s severe clinical mani-
festations were unlikely to be explained by the diagnosis of
isolated IgA deficiency, an autosomal recessive disorder was
suspected. We discovered and here describe a novel, homo-
zygous missense mutation in C3, altering a highly conserved
amino acid found in the first position of the C345C domain of
the C3 protein which is hypothesized to function as a binding
site for factor B, as required for C3 convertase formation
[20–22]. This domain is known to undergo large rearrange-
ments upon activation and is present in the C3b molecule [23,
24]. Furthermore, this cysteine residue forms one of the disul-
fide bonds in the C3 protein [20, 25], thus its loss will likely
affect protein folding and/or stability.
After vaccination for S. pneumoniae, our patient showed a
marked clinical improvement. In line with this observation, it
has been shown that mice depleted for C3 by intraperitoneal
injection of cobra venom factor which are immunized against
S. pneumoniae have reduced sepsis when colonized with this
bacterium compared to control or neutrophil-depleted mice
[26]. Previous studies have illustrated that C3-deficient
patients are able to mount adaptive immune responses to
conjugated vaccines against S. pneumoniae [8, 9].
As mentioned, in addition to C3 deficiency the patient
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Fig. 2 Pedigree and genetic analysis of the core family (2a) and
phylogenetic conservation of the cysteine 1518 in C3 (2b). a Perfect
segregation of the C3 mutation (c. C4554G, p. Cys1518Trp) is shown
in the patient and parents. Females are represented as circles and males
as squares. Filled and half-filled symbols represent homozygous and
heterozygous individuals, respectively. The point mutation is marked
with a grey bar. The segregation in the siblings is not shown. b
Phylogenetic conservation of the mutated amino acid in C3 in verte-
brates. Cysteine 1518 is indicated with a red box
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most common form of primary immunodeficiency defined
by decreased levels of IgA in the presence of normal levels
of other immunoglobulin isotypes (reviewed in [27]).
Patients are predisposed to recurrent sinopulmonary infec-
tions, gastrointestinal disorders, autoimmune diseases, atopy
and malignancies [27, 28]. Amongst the gastrointestinal
disorders, giardiasis, malabsorption, lactose intolerance, ce-
liac disease, ulcerative colitis and nodular lymphoid hyper-
plasia can be found [27]. Respiratory tract infections are the
most frequent morbidities in sIgAD patients [28], however,
bronchiectasis is a rare complication [29]. Although sIgAD
is often asymptomatic, patients with concomitant IgG2 de-
ficiency may present with impaired antibody responses
against polysaccharide antigens and show predisposition to
more severe bacterial infections [28].
Besides C3 deficiency, other deficiencies of adaptive or
innate immunity can also lead to increased susceptibility to
infections caused by S. pneumoniae, albeit with differences
in the clinical and laboratory findings (reviewed in [4, 12]).
Two interesting examples of such innate immune deficien-
cies are IRAK4 and MYD88 deficiency, respectively.
IRAK4- or MYD88-deficient patients are predisposed to
recurrent invasive infections with S. pneumoniae, especially
meningitis (reviewed in [12]). These patients also frequently
present with impaired ability to increase plasma C-reactive
protein and to mount fever in response to infection, with
spontaneous improvement in adolescence (reviewed in
Table 1 Description of the lab-
oratory findings of the patient
and parents
aTotal hemolytic complement
activity test. b In vitro lympho-
cyte stimulation with 20 µg/mL
of phytohemagglutinin for 72 h.
The values refer to the percen-
tages of the blastic transforma-
tion of lymphocytes (enlarged
nucleus, condensed chromatin
and/or with pores in the cyto-
plasm) evaluated using light mi-
croscopy. c Nitroblue tetrazolium
semiquantitative test for evalu-
ating neutrophil oxidative burst,
values refer to the percentages of
activated neutrophils presenting
with respiratory burst activity
1Patient examination at the age
of 16 years
2Normal values in age-matched
Turkish subjects
Patient1 Father Mother Reference values
Blood urea nitrogen (mg/dL) 26 20–40
Creatinine (mg/dL) 0,8 0,6–1,2
CH50a (U/mL) 0 71 71 >15
C3 levels (mg/dL) 8–19 63 71 90–1802
C4 levels (mg/dL) 20 10–40
IgA (mg/dL) <5.8 230 341 44–244





IgM (mg/dL) 86 52–297
IgE (IU/mL) 46 0–100
Anti-A titer 1/64 1/10
Anti-B titer 1/128 1/10
Tuberculin test (mm) 10 5–10
In vitro PHAb (%) 61 65.8±9.2
Unstimulated NBTc (%) 50 0–38
Stimulated NBTc (%) 70 60–90
Total lymphocyte counts (cell/mm3) 3500 1700–5700
T lymphocytes (CD3+) (%) 68 55–79
(cells/mm3) 2040 1100–4100
T helper cells (CD4+) (%) 38 28–51
(cells/mm3) 1140 600–2400
Cytotoxic T cells (CD8+) (%) 26 16–42
(cells/mm3) 780 400–1500
Natural killer cells (CD16+56+) (%) 7 5–28
(cells/mm3) 210 200–1000
B lymphocytes (CD19+) (%) 20 10–28
(cells/mm3) 600 200–1400
Table 2 Specific IgG antibody levels in the patient before and after S.
pneumoniae vaccine (U/mL). Reference values: ≥20 U/mL
Serotypes 3 6B 14 19F 23F 7F
Before vaccination 22 16 32 19 16 18
6 weeks after vaccination 29 >100 46 65 68 20
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[12]). By contrast, our patient presented mainly with pneu-
monias, and similar to other C3-deficient patients [4, 5], he
showed high levels of CRP and had episodes of fever, with
infectious episodes persisting throughout adolescence.
Taken together, the following observations support our
hypothesis that the clinical phenotype of our patient was - at
least predominantly - caused by the underlying deficiency in
C3 rather than associated with sIgAD: 1) sinusitis or gas-
trointestinal disorders are absent in the patient; 2) bronchi-
ectasis is observed although our patient presented with
normal IgG2 levels and normal antibody responses to poly-
saccharide antigens; 3) the patient displays a marked and
relatively specific susceptibility to infections with encapsu-
lated bacteria such as S. pneumoniae; and 4) there was a
marked clinical amelioration upon vaccination against S.
pneumoniae.
Conclusions
We here report a novel homozygous mutation in C3 in a
patient with recurrent and severe infections caused by Strep-
tococcus pneumoniae and associated IgA deficiency. The
case presented here highlights the importance of a more
thorough evaluation of sIgAD patients when the clinical
presentation is unusual or more severe than expected. In
case of severe infections caused by encapsulated agents
such as S. pneumoniae, a careful evaluation of complement
components is mandatory. Our data lend further support to
the concept that vaccination against this microorganism is
critical for immunodeficient patients, in particular for
inherited complement deficiencies.
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